Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbon-ion radiotherapy plus gemcitabine for locally advanced pancreatic cancer (J-CROS 1502 Pancreas)
jRCT1031190131Active, not recruiting
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gemcitabine in pancreatic adenocarcinoma (PDAC). Primary endpoint: Overall survival rate at 2 years. Started Mar 2017; status: active, not recruiting.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT1031190131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031190131.